SEC Form 4 · accession 0001562180-18-001355
PROGENICS PHARMACEUTICALS INC · PGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bryce Tenbarge
Officer — SVP, Commercial
Period of report
Mar 1, 2018
Accepted (ET)
Mar 2, 2018 · 1:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000835887
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $6.62 | Mar 1, 2018 | A | 75,900 | A | — | Mar 1, 2028 | Common Stock | 75,900 | 75,900 | D |
Explanation of responses
- F13yr 33% On Vest beginning on 01-Mar-2018